Blog
RSS FeedPosted by Michael Wonder on 09 Dec 2020
Canada health regulator approves Pfizer's COVID-19 vaccine
10 December 2020 - Canada’s health regulator has approved Pfizer’s COVID-19 vaccine. ...
Posted by Michael Wonder on 02 Dec 2020
Health Canada licenses Xeomin (incobotulinumtoxinA) for adult patients with sialorrhea
1 December 2020 - Merz Therapeutics today announced Health Canada’s notice of compliance for Xeomin (incobotulinumtoxinA) for the treatment of chronic ...
Posted by Michael Wonder on 26 Nov 2020
Lynparza (olaparib) receives Health Canada approval for the treatment of BRCA or ATM gene-mutated metastatic castration-resistant prostate cancer
25 November 2020 - On 21 August 2020, Health Canada approved Lynparza (olaparib), for the treatment of adult patients with deleterious ...
Posted by Michael Wonder on 24 Nov 2020
Rigel and Medison announce Health Canada approval of Tavalisse, an oral medication for the treatment of adults with chronic immune thrombocytopenia
23 November 2020 - Rigel Pharmaceuticals and Medison Pharma today announced that Health Canada has approved the new drug submission ...
Posted by Michael Wonder on 20 Nov 2020
Lilly's neutralising antibody bamlanivimab (LY-CoV555) receives interim authorisation from Health Canada as a treatment for COVID-19
20 November 2020 - Bamlanivimab emerged from collaboration between Lilly and Vancouver-based AbCellera. ...
Posted by Michael Wonder on 18 Nov 2020
HLS Therapeutics announces Health Canada approval of Perseris for the treatment of schizophrenia
17 November 2020 - First once-monthly risperidone long-acting injectable used in the treatment of schizophrenia. ...
Posted by Michael Wonder on 18 Nov 2020
Dupixent (dupilumab injection) now approved by Health Canada for patients with severe asthma
17 November 2020 - Only biologic approved in Canada to treat severe asthma with type 2 / eosinophilic phenotype, or oral ...
Posted by Michael Wonder on 13 Nov 2020
Health Canada extends approval of Imvamune to immunisation against monkeypox and orthopox viruses
12 November 2020 - Bavarian Nordic announced today that Health Canada has expanded the approval of the Company’s non-replicating smallpox ...
Posted by Michael Wonder on 10 Nov 2020
Health Canada approves Maviret 8 week treatment duration for treatment naïve patients with genotype 3 compensated cirrhosis
10 November 2020 - Maviret (glecaprevir/pibrentasvir) is the only 8 week oral treatment approved for all hepatitis C virus genotypes. ...
Posted by Michael Wonder on 04 Nov 2020
Health Canada approves Canada’s first HIV self test
3 November 2020 - For the first time, Canadians will have access to at-home HIV self test kits. bioLytical Laboratories ...
Posted by Michael Wonder on 02 Nov 2020
Novartis' MONALEESA-7 Kisqali (ribociclib succinate) study demonstrated statistically significant improvement in overall survival in pre- and peri-menopausal women with HR+/HER2- advanced breast cancer
2 November 2020 - Novartis Pharmaceuticals Canada is pleased to announce that statistically significant overall survival results for Kisqali (ribociclib succinate) ...
Posted by Michael Wonder on 28 Oct 2020
KYE Pharmaceuticals announces commercial availability of Firdapse in Canada
28 October 2020 - KYE Pharmaceuticals today announced an important milestone, Firdapse (amifampridine phosphate), the first amifampridine product approved in Canada, ...
Posted by Michael Wonder on 20 Oct 2020
Health Canada has approved Taltz (ixekizumab) for the treatment of non-radiographic axial spondyloarthritis
19 October 2020 - Taltz is now approved to treat patients across the axSpA spectrum, including ankylosing spondylitis and non-radiographic axSpA. ...
Posted by Michael Wonder on 17 Oct 2020
Health Canada approves Keytruda (pembrolizumab) as first-line treatment for patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma
15 October 2020 - Approval Based on Significant Overall Survival Findings from Phase 3 KEYNOTE-048 Trial. ...
Posted by Michael Wonder on 15 Oct 2020
Health Canada approves first-ever gene replacement therapy, Luxturna
15 October 2020 - Luxturna (voretigene neparvovec), is the first approved therapy for previously untreatable inherited retinal disease. ...